Tune in today at 11:45 AM ET to hear our CFO Lauren White & COO Eric Green present at the Oppenheimer Private Life Sciences Company Showcase. Live webcast: bit.ly/4nllNke & replay available on our website: seaporttx.com/news-papers/

We’re a Fierce Biotech Fierce 15 winner! Our Glyph platform, proven team, & focus on validated mechanisms put us among the most “innovative & visionary” companies as we advance clinical programs aiming to deliver new medicines for #depression & #anxiety. bit.ly/4msojnm

Looking forward to two upcoming investor conferences: 1x1s & company presentation at Oppenheimer's Private Life Sciences Company Showcase on 9/25 at 11:45am ET & 1x1s at the 5th Annual Needham Private Biotech & MedTech Company Forum, held 10/14-10/15. bit.ly/42z6Fr1

Pleased to share the first participant has been dosed in our Ph1 study of GlyphAgo™ (SPT-320). This is our 2nd therapeutic candidate in clinical development & represents an important clinical advancement for patients w/GAD. bit.ly/4meQFl0

Dan Bonner, Co-Founder & SVP, Platform at Seaport will present at the Neuropsychiatric Drug Development Summit in Boston on 9/11 at 1:30pm to share insights on the discovery & selection of novel lymphatic-targeted prodrug candidates using clinical evidence ter.li/42ap36

Congrats to COBENFY & ZURZUVAE teams for 2025 #PrixGalien Best Pharmaceutical Product noms! Kudos to all involved (@PureTechh, Karuna for COBENFY) in the successful journeys, notably Seaport's Dr. Steve Paul for his role in advancing both nominated drugs bit.ly/3V6cx72

This summer, the team had a blast together building meaningful connections. From everyday moments to unique outings, these experiences reinforce our bonds & remind us of our shared mission to serve those with #MentalHealth conditions like #depression & #anxiety. Excited for more!

We're featured in @natbiotech.nature.com's “Editor’s Pick” for our work developing #neuropsychiatric medicines using our proprietary Glyph platform. Read about how we're advancing novel therapies with clinically validated mechanisms for depression & anxiety bit.ly/47f4jke

Our CFO, Lauren White, joins Boston Business Journal's “Biotech’s Future – Innovation, AI and our Competitive Edge” panel this Thursday with other industry leaders to discuss the future of biotech & life sciences in MA. Don’t miss this dynamic discussion! bit.ly/44VDFLK

CEO @daphnezohar.bsky.social took Brad Loncar @biotechtv.bsky.social on a tour of our office located in heart of Boston’s Seaport District, which is uniquely designed to foster collaboration, happiness & teamwork as we work together to develop new medicines for #depression & #anxiety. Check it out!

For @biotechtv.bsky.social's Biotech CEO Sisterhood series, our CEO @daphnezohar.bsky.social spoke to Sophie Kornowski on her journey leading Boston Pharmaceuticals to a $2B deal w/ GSK. Check this out for insights from both leaders on dealmaking, leadership strategies & mentorship: bit.ly/4m55kzG

Pleased to announce the first patient has been dosed in our Ph2b BUOY-1 study of GlyphAllo™ (SPT-300) in #MDD w/ or w/o anxious distress, an important milestone for Seaport’s pipeline that brings us closer to a potential new treatment for patients w/ MDD: bit.ly/3Uhn3YB

The Seaport crew kicked off summer with a fun gathering! Great opportunity to connect out of the office, strengthening our mission to develop life-changing medicines for #neuropsychiatric disorders. Looking forward to more moments together and progress towards transforming lives!

Our Co-founder & Board Chair Dr. Steve Paul was at Royalty Pharma’s #ABI25 for a fireside chat on the neuropsych renaissance. A pioneer in neuropsychiatric drug development, he shared insights into this new era of CNS medicines, including Seaport’s work in #depression & #anxiety

As #MentalHealthMonth closes, we welcomed a @namicommunicate.bsky.social patient representative to share his journey w/ mental health conditions. His story inspires our work at Seaport to help those struggling & develop new medicines for #depression & #anxiety. More: www.nami.org

This #MentalHealthMonth, we joined @namicommunicate.bsky.social's annual #NAMIWalks to combat stigma & promote mental health awareness. We stand with those affected by mental illness & are dedicated to developing new medicines for #depression & #anxiety. More about NAMI www.nami.org

Our CMO Tony Loebel & @afspnational.bsky.social board member attended the 2025 Lifesavers Gala to honor progress in the fight against suicide. In recognition of #MentalHealthAwarenessMonth, we're proud Tony represented Seaport to help save lives & bring hope to those affected by suicide.

#Depression & #anxiety are among the most common & disabling #mentalhealth conditions. This #MentalHealthAwarenessMonth we're spotlighting our commitment to developing better medicines & reducing the stigma for those dealing w/these conditions. Learn more: www.seaporttx.com

"Neurology is back” as detailed in Nature Biotech spotlighting "Seaport’s approach, like that of Karuna, is to resurrect drugs that showed clinical efficacy, but which had other issues that limited their impact on patients." Also mentioned $JNJ, $RAPP, $BHVN & others: doi.org/10.1038/s415...

We're at #SOBP2025 to present new preclinical data on SPT-320, a novel oral prodrug of agomelatine. SPT-320 increased lymphatic transport >50% compared to <1% agomelatine alone & increased plasma exposure >10-fold. SPT-320 progressing into clinic for #GAD. bit.ly/4ixtOzs

Congrats @daphnezohar.bsky.social, named to @statnews.com #STATUSList, "the ultimate list of leaders in health, medicine, & science," for founding Seaport & raising $325M. “That’s big & her influence on the biotech field extends beyond that” & cofounding Karuna & PureTech bit.ly/4coOF6B

Seaport aims to develop better treatments for depression & anxiety. This commitment comes from our exceptional team, all rowing in the same direction to deliver new drugs to make the lives of patients better. What inspires us daily? Hear from our team!

1 year ago, we launched w/ a mission to deliver new medicines to those suffering from depression & anxiety. What a year! We raised $325M, built a stellar team, shared important scientific & clinical work, & advanced our clinical-stage pipeline & Glyph platform: seaporttx.com

Listen in today at 3:45pm EDT as Michael Chen, our Co-Founder and CSO and Lauren White our CFO present at the 24th Annual Needham Healthcare Conference.  Tune in here: bit.ly/4hWh4lq In case you missed it: seaporttx.com/news-papers/

Pleased to announce our participation in two investor conferences in April. Our Seaport management team will present at the 24th Annual Needham Healthcare Conference on April 7 at 3:45pm EDT and will take part in Citi Biotech Private Access Day on April 24. bit.ly/4hWnJMz

Yesterday our Co-founder & CEO, @daphnezohar.bsky.social, spoke at @massbio.bsky.social's #StateofPossible25 participating in a panel with the Biotech CEO Sisterhood, discussing their journeys as business leaders, challenges faced and mutual support through their networks.

Today our Co-founder & CEO @daphnezohar.bsky.social will present at Stifel 2025 Virtual CNS Forum. She will be joined by Co-Founder & Board Chair Steve Paul, M.D., & Co-Founder & CSO, Michael Chen, Ph.D., for the Q&A session. Tune in at 2pm EDT: wsw.com/webcast/stif...

Today we welcomed Bob Hombach to our Board of Directors as the Chair of the Audit Committee. His 3 decades of experience includes CFO Baxter ($BAX) & Baxalta ($BXLT) plus Board positions at FORTUNE 500 companies like BioMarin ($BMRN) & Henry Schein ($HSIC). bit.ly/4iDs08j

Upcoming Investor Conferences in March: Our management team was invited to participate in the Leerink Partners Global Healthcare Conference 2025, March 10-12th and will present at the Stifel 2025 Virtual CNS Forum on March 19th at 2pm EDT. More details: bit.ly/3QGAU97

Our team was at #ISCTM to present a meta-analysis exploring the impact of clinical trial design factors on placebo effect in #MDD trials. Key finding links number & frequency of clinician-administered assessments to increased placebo response. Read more: bit.ly/3Qsz8bx

Today we announced new research demonstrating increased lymphatic transport w/ up to 55% drug absorption via lymphatics & 2-fold higher release in lymph nodes w/Glyph compared to previously reported linkers. Further evidence supports innovation of Glyph: bit.ly/4hy4pG5

Delighted to be named one of 25 Startups to Watch by the Boston Business Journal! Being recognized as a company “on the verge of something big” fuels our commitment to changing lives of patients & families dealing w/ depression & anxiety. View full list spanning all industries bit.ly/3XdJhgj

We're at #MBCF2025 to present data that demonstrates enhanced oral bioavailability of our clinical-stage candidate, SPT-300, and validates the ability Glyph to design new candidates with human drug exposure from a set of tailored preclinical assays. bit.ly/4jDxUrz

Seaport is seeking a talented & entrepreneurial Program Leader (PL) to quarterback our SPT-300 program w/ potential to make an impact on patients globally. This is a high-profile role working directly w/ our CEO @daphnezohar.bsky.social. Check out this opportunity to join our team! bit.ly/3PX3rqJ

Our Co-founder & CEO, Daphne Zohar, took the stage at #JPM25 today to present the Seaport story & our ongoing work to change the lives of patients suffering from #depression & #anxiety. Co-founders, Dr. Steve Paul, Board Chair, & Michael Chen, CSO, joined her onstage for Q&A.

We're pleased to be recognized by BioSpace on the NextGen: Class of 2025 list of the hottest new life science companies! Check out the full list including a nice snapshot on Seaport: www.biospace.com/nextgen

Our Co-founder & CEO, Daphne Zohar, will present at the J.P. Morgan Healthcare Conference on Monday, Jan 13at 9:30am PST. She will be joined by Steve Paul, M.D., Co-founder & Board Chair, & Michael Chen, Ph.D., Co-founder & CSO during the Q&A portion seaporttx.com/press-releas...

This week, we moved into our new space & celebrated our team & core values as we reflected on the rapid progress since our launch. We look forward to more moments together as we work toward our ultimate goal of making a difference for those impacted by #depression & #anxiety.

This New York Times article spotlighting 7 things everyone should know about antidepressants calls attention to the tremendous need for better medicines that help address unfavorable side effects, modest efficacy, & weeks delay to work for patients: nyti.ms/49AXN6x

We're at #ACNP2024 presenting additional data from our Ph1 study of SPT-300, an oral prodrug of allopregnanolone. The poster includes further safety analysis & PK-PD data, & identifies well-tolerated doses w/PD activity to be included in Ph2b MDD study t.co/meYNduGE1C